Bioprosthetic valves are being used more and more for aortic valve replacement, but mechanical valves appear to provide better long-term outcomes for patients 60 and younger. The new study, based on data from nearly 110,000 patients, was presented at STS 2025 and published in the Journal of the American College of Cardiology.

Cardiac surgeon Joseph F. Sabik III, MD, is an established clinical researcher and has held several committee positions with STS over the years.

Cardiologists believe this is the first time this exact complication has been reported. Even patients who present with no known risk factors, they said, should receive regular follow-up care to ensure such incidents do not go untreated. 

In addition, researchers noted, five-year mortality was inferior for patients on Medicaid when compared to patients with any other type of insurance. 

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business. 

Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.

Meril Life Sciences has been manufacturing its Myval heart valves for years. The devices are approved and available in both India and Europe, but they have not been approved by the FDA.